Novo Nordisk Wins EU Authorisation for Haemophilia A Treatment
The European Commission authorised FREHEMGO (denecimig) for routine prophylaxis in adults and children with haemophilia A, with or without inhibitors. Dosing options are monthly, every two weeks or weekly.
The European Commission granted marketing authorisation for FREHEMGO (denecimig) as routine prophylaxis for adults and children with haemophilia A, with or without inhibitors. The treatment offers monthly, every-two-weeks or weekly dosing.Material DetailsContext by AI AnalystThis is a regulatory mi…